Studies show the peptide may reduce inflammation associated with adjuvant-induced arthritis, periodontitis, and various autoimmune condition models
Tirzepatide is administered subcutaneously once weekly and works by activating GIP and GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite
[DOI] [PMC free article] [PubMed] [Google Scholar] 40.Patents and regulatory exclusivities on GLP-1 receptor agonists
Additionally, due to inherent proclivity to hemolytic, thrombotic, and other medically threatening events, G6PD-deficient patients may be limited in treatment options available to them, particularly in the case of COVID-19 infection
Yamagishi K, Nettleton JA, Folsom AR, Investigators AS
Injection-related anxiety Some individuals experience distress related to self-injection, which can compound anxiety if not addressed with education and support